Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alphamab Oncology ( (HK:9966) ) has issued an announcement.
Alphamab Oncology announced that its new drug application for KN026, a bispecific antibody for HER2+ gastric cancer, has been accepted by China’s National Medical Products Administration. This marks a significant advancement as KN026 is the first anti-HER2 therapy in China to show positive results for second-line treatment of gastric cancer, potentially enhancing the company’s market position and offering new hope for patients who have exhausted other treatment options.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a leading biopharmaceutical company in China, specializing in antibody-drug conjugates, bispecific antibodies, and multi-functional protein engineering. The company has a diverse pipeline of oncology-focused products, including monoclonal and bispecific antibodies, with one product approved for marketing by the NMPA and several others in advanced clinical trial stages.
Average Trading Volume: 3,953,225
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.58B
Find detailed analytics on 9966 stock on TipRanks’ Stock Analysis page.